EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use

Katie B Olney iD, Jenni K Thomas iD, Wes M Johnson iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-07 · 43 (7) · 713-731

DOI: 10.1002/phar.2782 ↗

At a glance

Übersichtsarbeit in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2023-03-12. Written by Katie B Olney and 2 co-authors. Institution: Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA. Major MEDLINE topics: beta-Lactamase Inhibitors, Lactams. Cited 12 times so far (Crossref); 116 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Antimicrobial resistance continues to surmount increasing concern globally, and treatment of difficult‐to‐treat (DTR) Pseudomonas aeruginosa , carbapenem‐resistant (CR) Acinetobacter baumannii (CRAB), and CR Enterobacterales (CRE) remains a challenge for clinicians. Although previously rare, the incidence of multidrug‐resistant (MDR) and CR infections in pediatric patients has increased drastically in the last decade and is associated with increased morbidity and mortality. To combat this issue, 14 novel antibiotics, including three β‐lactam/novel β‐lactamase inhibitor combinations (βL‐βLIs) and two novel β‐lactams (βLs), have received approval from the United States Food and Drug Administration since 2010. Improving clinician understanding of the utility of these novel therapies is imperative to improve judicious decision‐making and prevent societal regression to a pre‐penicillin era. In this review, we summarize the pharmacokinetic/pharmacodynamic (PK/PD) properties, clinical efficacy and safety data, dosing considerations, and subsequent role in therapy for ceftazidime‐avibactam (CAZ‐AVI), meropenem‐vaborbactam (MER‐VAB), imipenem‐cilastatin‐relebactam (IMI‐REL), ceftolozane‐tazobactam (TOL‐TAZ), and cefiderocol in pediatric patients.

Subjects

MeSH terms (MEDLINE)

beta-Lactamase InhibitorsLactamsUnited StatesHumansChildAnti-Bacterial AgentsDrug CombinationsAzabicyclo CompoundsMicrobial Sensitivity Tests

Author keywords

bacterial resistancebeta-lactamspediatrics

Substances

beta-Lactamase InhibitorsLactamsAnti-Bacterial AgentsDrug CombinationsAzabicyclo Compounds

Authors and institutions

  • Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA.

ORCID profiles: Katie B Olney, Jenni K Thomas, Wes M Johnson

Cite

APA

Olney, K. B., Thomas, J. K., & Johnson, W. M. (2023). Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(7), 713-731. https://doi.org/10.1002/phar.2782

Vancouver

Olney KB, Thomas JK, Johnson WM. Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(7):713-731. doi:10.1002/phar.2782

BibTeX
@article{Olney2023,
  author = {Olney, Katie B and Thomas, Jenni K and Johnson, Wes M},
  title = {Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  volume = {43},
  number = {7},
  pages = {713--731},
  doi = {10.1002/phar.2782}
}
Start for free →